Difference between revisions of "Aop:167"
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
− | + | = Status = | |
− | {{ | + | <span style="color:#FF0000"> |
+ | This is a legacy representation of this AOP. Please see the current version here: | ||
+ | |||
+ | [//{{SERVERNAME}}/aops/167 https://{{SERVERNAME}}/aops/167] | ||
+ | </span> | ||
+ | |||
+ | |||
== AOP Title == | == AOP Title == | ||
<div id='longTitle' class='Title'> Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. </div> | <div id='longTitle' class='Title'> Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. </div> |
Latest revision as of 23:38, 11 December 2016
Status
This is a legacy representation of this AOP. Please see the current version here:
AOP Title
Authors
Cancer AOP Workgroup. National Health and Environmental Effects Research Laboratory, Office of Research and Development, Integrated Systems Toxicology Division, US Environmental Protection Agency, Research Triangle Park, NC. Corresponding author for wiki entry (wood.charles@epa.gov)
Status
Please follow the link to snapshots page to view and create Snapshots of this AOP.
Under development: Do not distribute or cite.
OECD Project 1.29: A catalog of putative AOPs that will enhance the utility of US EPA Toxcast high throughput screening data for hazard identification
This AOP page was last modified on 12/11/2016.
Click here to show/hide revision dates for related pages
Page | Revision Date/Time |
---|
Abstract
This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.
Background (optional)
Summary of the AOP
Please follow link to widget page to edit this section.
If you manually enter text in this section, it will get automatically altered or deleted in subsequent edits using the widgets.
Molecular Initiating Event
Molecular Initiating Event | Support for Essentiality |
---|---|
Estrogen receptor (ER) activity, prepubertal increase | Strong |
Key Events
Adverse Outcome
Adverse Outcome |
---|
adenosquamous carcinomas of endometrium, Increased |
Relationships Among Key Events and the Adverse Outcome
Network View
Cytoscape Web will replace the contents of this div with your graph.
Click nodes or edges.
Life Stage Applicability
Life Stage | Evidence | Links |
---|---|---|
Fetal to Parturition | Moderate | |
Juvenile | Moderate |
Taxonomic Applicability
Name | Scientific Name | Evidence | Links |
---|---|---|---|
mouse | Mus musculus | Strong | NCBI |
Sex Applicability
Sex | Evidence | Links |
---|---|---|
Female | Strong |
Graphical Representation
Click to upload graphical representation
Overall Assessment of the AOP
Domain of Applicability
Life Stage Applicability,
Taxonomic Applicability,
Sex Applicability
Elaborate on the domains of applicability listed in the summary section above. Specifically, provide the literature supporting, or excluding, certain domains.
Essentiality of the Key Events
Molecular Initiating Event Summary,
Key Event Summary
Provide an overall assessment of the essentiality for the key events in the AOP. Support calls for individual key events can be included in the molecular initiating event, key event, and adverse outcome tables above.
Weight of Evidence Summary
Summary Table
Provide an overall summary of the weight of evidence based on the evaluations of the individual linkages from the Key Event Relationship pages.
Quantitative Considerations
Summary Table
Provide an overall discussion of the quantitative information available for this AOP. Support calls for the individual relationships can be included in the Key Event Relationship table above.
Considerations for Potential Applications of the AOP (optional)
References
1. Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C., David, R. M., DeLuca, J. G., Lai, D. Y., McKee, R. H., Peters, J. M., Roberts, R. A., and Fenner-Crisp, P. A. (2003). PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Critical reviews in toxicology 33(6), 655-780, 10.1080/713608372.
2. Newbold, R. R., Banks, E. P., Bullock, B., and Jefferson, W. N. (2001). Uterine adenocarcinoma in mice treated neonatally with genistein. Cancer research 61(11), 4325-8.
3. Suen, A. A., Jefferson, W. N., Wood, C. E., Padilla-Banks, E., Bae-Jump, V. L., and Williams, C. J. (2016). SIX1 Oncoprotein as a Biomarker in a Model of Hormonal Carcinogenesis and in Human Endometrial Cancer. Molecular cancer research : MCR doi: 10.1158/1541-7786.MCR-16-0084, 10.1158/1541-7786.MCR-16-0084.